This research was presented in part at the 33rd Annual Scientific Meeting of the Infectious Diseases Society for Obstetrics and Gynecology, Monterey, CA, 3–5 August 2006.
Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation†
Version of Record online: 7 AUG 2013
© 2013 The Authors BJOG An International Journal of Obstetrics and Gynaecology © 2013 RCOG
BJOG: An International Journal of Obstetrics & Gynaecology
Volume 120, Issue 12, pages 1534–1547, November 2013
How to Cite
Time to viral load suppression in antiretroviral-naive and -experienced HIV-infected pregnant women on highly active antiretroviral therapy: implications for pregnant women presenting late in gestation. BJOG 2013;120:1534–1547., , , , , , , , .
- Issue online: 11 OCT 2013
- Version of Record online: 7 AUG 2013
- Manuscript Accepted: 22 FEB 2013
- UCSF-CTSI. Grant Number: UL1 TR000004
- 8British HIV Association. Management of HIV infection in pregnant women. 2008 [www.bhiva.org]. Accessed 1 November 2011.
- 9World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants. 2010 [www.who.int]. Accessed 1 November 2011.
- 10Antiretroviral Pregnancy Registry Steering Committee. Antiretroviral pregnancy registry international interim report for 1 Jan 1989 – 31 January 2011. Wilmington, NC: Registry Coordinating Center. 2011 [www.APRegistry.com]. Accessed 1 November 2011.
- 11Perinatal HIV Guidelines Working Group. Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV Transmission in the United States. September 14, 2011; pp 1–207. [http://aidsinfo.nih.gov/contentfiles/lvguidelines/PerinatalGL.pdf]. Accessed November 1, 2011.
- 14Characterization of viral dynamics in human immunodeficiency virus type 1-infected patients treated with combination antiretroviral therapy: relationship to host factors, cellular restoration, and virologic end points. J Infect Dis 1999;179:799–807., , , , , , et al.
- 15Time to clinically significant viral suppression in HIV-infected pregnant women. Presented at 24th Annual Meeting of the Society of Maternal Fetal Medicine; 2004; New Orleans, Louisiana. Obstet Gynecol 2003;189:S102., , , , , , et al.
- 17Time to HIV suppression with HAART in pregnancy. Presented at the 14th Annual Meeting of the Conference on Retroviruses and Opportunistic Infections. 2007; Los Angeles, California. [www.retroconference.org/2007/Abstracts/28669.htm]. Accessed November 2011., , , , , , et al.
- 18Early viral load reduction in pregnant women differs according to antiretroviral regimen. Presented at the 15th Annual Meeting of the Conference on Retroviruses and Opportunistic Infections. 2008; Boston, Massachusetts. [www.retroconference.org/2008/Abstracts/31977.htm]. Accessed November 2011., , , , .
- 24Stanford University HIV Drug Resistance Database. [http://hivdb.stanford.edu]. Accessed April 2009.
- 25Regression Methods in Biostatistics: Linear, Logistic, Survival, and Repeated Measures Models, 2nd edn. New York: Springer, 2012., , , .
- 27Virologic and clinical outcomes in HIV-infected pregnant women: directly observed therapy can overcome barriers to care. Presented at the 11th Annual Meeting of the Conference on Retroviruses and Opportunistic Infections. 2004; San Francisco, California. [www.retroconference.org/2004/cd/Abstract/922.htm]. Accessed November 2011., , , .
- 32Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recommen Rep 2006;55(RR-14):1–17., , , , , , et al.
- 33Efficacy and safety of cesarean delivery for prevention of mother-to-child transmission of HIV-1. Cochrane Database Syst Rev 2005;4:CD005479., .